ValMed
Using digital technology to understand the impact and value of particular medicines on individual patients
Using digital technology to understand the impact and value of particular medicines on individual patients
The Digital Health & Care Innovation Centre, in collaboration with the University of Strathclyde, has been working to identify ways to determine what treatments are best for patients and how treatments perform in the real world compared to controlled clinical trials. In particular, the use of digital technologies to collect real-world evidence (RWE) may provide answers to some of these questions.
The aim of this project was to define the current state (As Is) and propose the future options (To Be) by which medicines can be assessed and evaluated using digital solutions and to develop a top-level specification and early paper prototype of a ValMed system exemplified this via a use case focusing on Enzalutamide and Abiraterone for prostate cancer.
By adopting digital health transformation approaches the project will demonstrate how it can benefit patients, clinical staff and NHS organisations.
The main impacts will be to:
Janssen and the Digital Health & Care Innovation Centre, working with academics from the University of Strathclyde, identified a need for the development of digital approaches to outcome measurement to be used in medicines value assessment using real-world evidence, integrating and supporting care pathways and resource allocation decisions.
Janssen commissioned DHI and academics from the University of Strathclyde to develop an approach to address this need.
The focus being:
To allow us to understand the impact and value of particular medicines on individual patients.
To do this we need to develop a methodology to use real-world data to assess patient outcomes.
This methodology will include:
Prostate cancer was the chosen illness because:
Janssen commissioned the Digital Health & Care Innovation Centre, working with academics from the University of Strathclyde to develop an approach to address this need.
Janssen’s aims:
The partnership with the Digital Health & Care Innovation Centre and the University of Strathclyde was chosen due to our ability to complete ground-breaking research and our interest in patient-driven models of data capture
The potential outcomes will demonstrate how embracing digital health transformation approaches can benefit all by:
This is a complex piece of research and therefore:
Phase 1 is complete with the Digital Health & Care Innovation Centre and academics from the University of Strathclyde delivering:
The next steps in the project are to: